Quick Takeaways: Why It Matters? Medgene’s launch could be a meaningful de-risking event for cattle producers because it creates the first U.S. prescription vaccine option for a parasite with severe herd-level consequences and no approved treatment, potentially reducing losses from mortali...
Quick Takeaways: Why It Matters? The EUA makes ivermectin liquid a short-term, horse-only screwworm prophylaxis tool, adding another regulated option to the NWS armamentarium and slightly strengthening biosecurity for foals and wounded horses, but because protection lasts only 24 hours and...
Quick Takeaways: Why It Matters? Zoetis’ EC approval of Poulvac Procerta HVT-ND turns its single-dose, dual ND+Marek’s protection into a mainstream EU option, which should drive rapid adoption as producers shift from multi-vaccine schedules to a streamlined, in‑ovo or hatch-day protocol th...
Featured Article Cover Story Regulatory Updates Launch Product Launch PetMeds Receives New Acquisition Proposal Corporate transaction PetMed Express has received an unsolicited, non-binding proposal from SilverCape Investments to acquire all outstanding shares for $3.00 per share in cash. ...
Quick Takeaways: Why It Matters? ECO Animal Health’s EU launch of Ecovaxxin MS is a meaningful commercial milestone because it converts the company’s own R&D pipeline into a marketed product and gives it a differentiated position in poultry vaccines. With access to a market spanning mo...
Featured Article Cover Story Regulatory Updates Research Updates Product Launch Retail expansion Dechra Opens Global Headquarters in Boston Corporate update Dechra has opened its new global headquarters in Boston, strengthening its innovation footprint while supporting community programs t...
Quick Takeaways: Why It Matters? The Texas A&M study positions Pictor’s PictVet assay as a highly accurate, non‑invasive tool for monitoring Mycoplasma bovis–associated immune responses in beef cattle, supporting broader use of targeted proteomics in her...
Featured Article Cover Story Research Updates Regulatory Approval Product Launches Elanco Launches $25 Million Venture Fund Innovation platform Elanco Animal Health plans to launch Elanco Ventures, a $25 million corporate venture platform to back early-stage animal health innovation. Key h...
The US FDA’s 2025 animal health approvals highlight a transformative year for veterinary medicine, with major advances spanning companion animal therapeutics, livestock productivity, poultry health, parasitic disease management, diagnostics, oncology, and genetic innovation. The latest wav...
Quick Takeaways: Why It Matters? Elanco Ventures adds a structured, early-stage venture arm to Elanco’s strategy, giving the company a dedicated channel to access and co-develop emerging animal health technologies before they become mature competitors or acquisition targets. The ...
